您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > SR 2595
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
SR 2595
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
SR 2595图片
CAS NO:1415252-61-7
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
SR 2595 是 PPARγ 的反向激动剂,IC50 为 30 nM。
Cas No.1415252-61-7
化学名4'-[[5-[[[(1S)-1-[4-(1,1-dimethylethyl)phenyl]ethyl]amino]carbonyl]-2,3-dimethyl-1H-indol-1-yl]methyl]-[1,1'-biphenyl]-2-carboxylic acid
Canonical SMILESCC(N1CC2=CC=C(C3=CC=CC=C3C(O)=O)C=C2)=C(C)C4=C1C=CC(C(N[C@@H](C)C5=CC=C(C(C)(C)C)C=C5)=O)=C4
分子式C37H38N2O3
分子量558.7
溶解度≤5mg/ml in ethanol;10mg/ml in DMSO;10mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: 30 nM

SR 2595 is an inverse agonist of PPARγ.

The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) is the key regulator of adipogenesis and the pharmacological target of the thiazolidinedione class of insulin sensitizers. Activation of PPARγ by thiazolidinediones can promote adipogenesis at the expense of osteoblast formation.

In vitro: SR 2595 was identified as an inverse agonist of PPARγ that repressed both transactivation and expression of the adipogenic marker fatty acid-binding protein 4 in differentiating murine preadipocytes. Moreover, the repression of PPARγ with SR 2595 promoted osteogenesis in cultured human mesenchymal stem cells (MSCs), as demonstrated by calcium phosphatase deposition. In addition, SR 2595 could also increase the expression of bone morphogenetic proteins BMP2 and BMP6 in MSCs [1].

In vivo: To determine whether pharmacological PPARg repression would impair insulin sensitivity, SR2595 was administered chronically to lean C57BL/6J mice. The PK properties of SR2595 were sufficient to support once daily oral dosing at 20 mg/kg. Lean C57BL/6J mice treated with SR2595 showed no significant change in insulin sensitivity as measured by insulin tolerance test, nor fasting insulin levels. In addition, no change in food consumption or body weight was observed during the treatment period [1].

Clinical trial: So far, no clinical study has been conducted.

Reference:
[1] Marciano, D. P.,Kuruvilla, D.S.,Boregowda, S.V., et al. Pharmacological repression of PPARγ promotes osteogenesis. Nature Communications 6, 1-7 (2015).